组蛋白甲基化研究进展

组蛋白甲基化是表观遗传修饰方式中的一种,参与异染色质形成、基因印记、X染色体失活和基因转录调控.组蛋白甲基化过程的异常参与多种肿瘤的发生.既往认为组蛋白甲基化是稳定的表观遗传标记,而组蛋白去甲基化酶的发现对这一观点提出了挑战,也为进一步深入研究组蛋白修饰提供新的途径.     

非编码RNA诱导的表观遗传学与肿瘤的发生

ncRNA可以通过多种遗传机理调控DNA的结构、RNA的表达和稳定性以及蛋白质的翻译和功能,最近研究证实小RNA可以通过指导基因组表现修饰DNA甲基化和组蛋白修饰引起癌遗传学途径基因失能与获能,增加基因组不稳定,印记丢失等途径参与肿瘤的发生发展.探索ncRNA对肿瘤细胞中基因的异常表达的影响和作用有助于将癌基因组学与表观遗传学的研究结合起来.为研发防治肿瘤的新方法和新途径提供新的思路.     

基因组DNA甲基化修饰在胚胎干细胞分化过程中的作用

基因组DNA的甲基化修饰通常使基因转录失活,去甲基化或低甲基化则使基因转录活化。但是,胚胎干细胞向各种成体细胞分化过程中相关基因的转录活化与DNA甲基化修饰水平并不呈简单的正性或负性相关。因此,甲基化修饰调节基因转录是一个复杂的过程。目前,对甲基化修饰作用的研究主要集中在基因选择性活化、改变转录因子与靶基因的结合活性、与组蛋白修饰协同作用及其基因表达的阶段特异性等方面。     

DNA甲基化与基因表达调控研究进展

表观遗传修饰是指不改变DNA序列的、可遗传的对碱基和组蛋白的化学修饰,主要包括DNA甲基化、组蛋白修饰、染色质重塑以及非编码RNA等.表观遗传修饰是更高层次的基因表达调控手段.DNA甲基化是一种重要的表观遗传修饰,参与基因表达调控、基因印记、转座子沉默、X染色体失活以及癌症发生等重要生物学过程.近年来随着研究方法和技术的进步,全基因组DNA甲基化的研究广泛兴起,多个物种全基因组甲基化图谱被破译,全局水平对DNA甲基化的研究不仅利于在宏观层面上了解DNA甲基化的特性与规律,同时也为深入分析DNA甲基化的生物学功能与调控奠定了基础.结合最新研究进展综述DNA甲基化在基因组中的分布模式、规律以及和基因转录的关系等.     

组蛋白甲基转移酶的研究进展

组蛋白的甲基化修饰主要是由一类含有SET结构域的蛋白来执行的, 组蛋白甲基化修饰参与异染色质形成、基因印记、X染色体失活和转录调控等多种主要生理功能, 组蛋白的修饰作用是表观遗传学研究的一个重要领域。组蛋白甲基化的异常与肿瘤发生等多种人类疾病相关, 可以特异性地激活或者抑制基因的转录活性。研究发现, 组蛋白甲基转移酶的作用对象不仅仅限于组蛋白, 某些非组蛋白也可以被组蛋白甲基转移酶甲基化, 这将为探明细胞内部基因转录、信号转导、甚至个体的发育和分化机制提供更广阔的空间。     

赖氨酸甲基转移酶PR-SET7及其生物学功能

PR-SET7, 也称SET8、KMT5a , 是现今发现唯一能够特异性单甲基化H4K20的赖氨酸甲基转移酶(Lysine methyltransferase, KMT)。在细胞周期不同时相PR-SET7的含量处于波动之中, 主要受泛素连接酶调节。PR-SET7与细胞增殖密切相关, 其催化的组蛋白H4K20单甲基化修饰在DNA复制、染色体固缩及细胞周期检验点激活中发挥重要调控作用。PR-SET7缺失将导致DNA损伤, 细胞周期阻滞, 甚至发生细胞凋亡。而且, PR-SET7可以调节ERa、Wnt、p53等多种基因的转录, 进而影响相应基因的表达。PR-SET7为个体发育所必需, 并参与了基因组印记的形成。另外, PR-SET7还能促进肿瘤的发生和转移, 有望成为肿瘤治疗的新靶点。文章主要从PR-SET7的结构、对组蛋白修饰的调节、在细胞周期、基因转录过程中的调控, 以及其在个体发育和肿瘤发生中的作用等方面综述了PR-SET7的研究进展。     

DNA甲基化与癌症

DNA甲基化是重要的表观遗传修饰,主要发生在DNA的CpG岛. DNA的甲基化通过DNA甲基转移酶（DNA methyltransferases, DNMTs）完成. DNA甲基化参与了细胞分化、基因组稳定性、X染色体失活、基因印记等多种细胞生物学过程.单基因水平及基因组范围内的DNA甲基化改变在肿瘤发生发展中亦发挥重要作用. 抑癌基因的异常甲基化引起的表达抑制,可导致肿瘤细胞的增殖失控和侵袭转移,并参与肿瘤组织的血管生成过程.在许多肿瘤的研究中都发现了基因组整体DNA低甲基化所导致的染色体不稳定性. 本文从DNA的异常高甲基化和低甲基化两方面论述了DNA甲基化在细胞恶变发生发展过程中的改变及其影响,并阐述了DNA甲基化改变在肿瘤诊断和治疗中的作用.     

组蛋白修饰酶对基因转录的调控

基因在转录过程中,需招募多种组蛋白修饰酶来对组蛋白进行化学修饰,这些化学修饰包括:组蛋白的甲基化、乙酰化、磷酸化、泛素化和SUMO化等.大多数组蛋白修饰酶能与不同的转录因子形成复合物,并引起组蛋白和DNA之间相互作用的改变,从而调控基因的转录.本文总结了各种组蛋白修饰酶复合物的组成、结构及功能方面的研究进展.     

组蛋白去甲基化酶与肿瘤发生

组蛋白甲基化修饰是一个可逆的动态的调节过程。甲基化和/或去甲基化状态与表观遗传、转录调控和维持基因组完整性等密切相关。组蛋白甲基化状态异常会直接或间接影响各种生理和病理过程。已知组蛋白去甲基化酶包括赖氨酸特异性去甲基化酶（LSD）家族和含JmjC结构域的JMJD家族。研究发现,两者与肿瘤的发生均有着密切的关系。本文总结了组蛋白去甲基化酶在组蛋白甲基化修饰及肿瘤研究方面的最新进展,为组蛋白修饰的功能及肿瘤诊断、治疗、预后监测等研究提供新思路。在胃癌、乳腺癌、结肠癌等常见肿瘤中,组蛋白去甲基化酶可改变组蛋白的甲基化水平或者直接作用于癌基因,也可调节microRNA或转录因子等,促进或抑制肿瘤的发生发展与影响肿瘤的预后。     

印记基因DLK1的研究进展

在哺乳动物中,有一部分特别的基因,它们由于受到印迹而只表达单一亲本的基因,这种表观遗传的修饰现象就是基因组印记,这有别于经典的孟德尔遗传学定律。DNA甲基化是一种重要的表观遗传修饰,主要的修饰部位发生在DNA的CpG岛,它参与了细胞分化,基因组稳定性、基因印记等多种细胞生物学过程,基因印迹的建立和维持是胚胎正常发育的基础,这一过程的实现有赖于各种DNA甲基化转移酶的精确表达和密切的配合。已发现在哺乳动物的基因组中存在着许多的印记基因,DLK1基因为父系表达母源沉默的印记基因,它的表达同样受到DNA甲基化的调节,它首先在神经母细胞瘤发现并克隆,定位于人类染色体14q32,属于表皮生长因子样超家族的成员之一,约有6个外显子。研究表明,DLK1基因在胚胎肝、早期肌肉组织以及造血干细胞等组织中均有表达,人DLK1基因全长1557bp,编码序列含有1152核苷酸,编码383个氨基酸残基,在人、小鼠、绵羊都存在保守序列,它参与多种细胞的增殖、分化并且与相关肿瘤的发生发展有着密切的关系,印迹基因的印迹异常与肿瘤的易感性及发生发展有重要的关系,本文就国内外DLK1基因的研究进展做一综述。     

Current progress in epigenetic research for hepatocarcinomagenesis

Hepatocellular carcinoma is the main type of primary liver cancer, and also one of the most malignant tumors. At present, the pathogenesis mechanisms of liver cancer are not entirely clear. It has been shown that inactivation of tumor suppressor genes and activation of oncogenes play a significant role in carcinogenesis, caused by the genetic and epigenetic aberrance. In the past, people generally thought that genetic mutation is a key event of tumor pathogenesis, and somatic mutation of tumor suppressor genes is in particular closely associated with oncogenesis. With deeper understanding of tumors in recent years, increasing evidence has shown that epigenetic silencing of those genes, as a result of aberrant hypermethylation of CpG islands in promoters and histone modification, is essential to carcinogenesis and metastasis. The term epigenetics refers to heritable changes in gene expression caused by regulation mechanisms, other than changes in the underlying DNA sequence. Specific epigenetic processes include DNA methylation, genome imprinting, chromotin remodeling, histone modification and microRNA regulations. This paper reviews recent epigenetics research progress in the hepatocellular carcinoma study, and tries to depict the relationships between hepatocellular carcinomagenesis and DNA methylation as well as microRNA regulation. Supported by National Basic Research Program of China (Grant No. 2006CD910402) and Science and Technology Commission of Shanghai Municipality (Grant No. 05DZ22201 and 08JC1416400).     

Epigenetic interplay of histone modifications and DNA methylation mediated by HDA6

One of the most fundamental questions in the control of gene expression is how epigenetic patterns of DNA methylation and histone modifications are established. Our recent studies demonstrate that histone deacetylase HDA6 integrates DNA methylation and histone modifications in gene silencing by interacting with DNA methyltransferase MET1 and histone demethylase FLD, suggesting that regulatory crosstalk between histone modifications and DNA methylation could be mediated by the interaction of various epigenetic modification proteins.     

Structural and functional features of the 5-methylcytosine distribution in the eukaryotic genome

DNA methylation is an integral part of the mechanism of a remodeling and modification of the chromatin structure. The global complex net of chromatin modification and remodeling reactions is still to be determined, and studies of the mechanisms controlling the epigenetic processes of histone modification and DNA methylation are in their infancy. Cytosine methylation occurs predominantly in CpG sequences of the eukaryotic genome, and it also takes place at symmetric CpHpG and nonsymmetric CpHpH sites (where H is A, T, or C). The modification efficiency of the three types of DNA methylation sites depends on their genomic localization. Different regions of the eukaryotic genome are remarkable for their methylation features: CpG-islands, CpG-island shores, differentially methylated regions of imprinted genes, and regions of nonalternative site-specific modification. The three canonical sites (CpG, CpHpG, and CpHpH) differ in DNA methylation efficiency depending on their nucleotide context. An epigenetic code of DNA methylation can be assumed with context differences playing a specific functional role. The review summarizes the main up-to-date data on the structural and functional features of site-specific cytosine methylation in eukaryotic genomes. Pathogenesis-related alterations in the methylation pattern of the eukaryotic genome are considered.     

Genomic DNA methylation: the mark and its mediators

Methylation of DNA at position five of the cytosine ring occurs at most CpG dinucleotides in the mammalian genome and is essential for embryonic viability. With several of the key proteins now known, it has become possible to approach the biological significance of this epigenetic system through both biochemistry and genetics. As a result, advances have been made in our understanding of the mechanisms by which DNA methylation is targeted to specific regions of the genome and interpreted by methyl-CpG-binding proteins. Recent studies have illuminated the role of DNA methylation in controlling gene expression and have strengthened its links with histone modification and chromatin remodelling.